[go: up one dir, main page]

NO20052041L - Administrasjonsform for farmasoytisk aktive peptider med vedvarende frigivelse og fremgangsmate for fremstilling av denne - Google Patents

Administrasjonsform for farmasoytisk aktive peptider med vedvarende frigivelse og fremgangsmate for fremstilling av denne

Info

Publication number
NO20052041L
NO20052041L NO20052041A NO20052041A NO20052041L NO 20052041 L NO20052041 L NO 20052041L NO 20052041 A NO20052041 A NO 20052041A NO 20052041 A NO20052041 A NO 20052041A NO 20052041 L NO20052041 L NO 20052041L
Authority
NO
Norway
Prior art keywords
preparation
sustained release
administration
pharmaceutically active
active peptides
Prior art date
Application number
NO20052041A
Other languages
English (en)
Other versions
NO338309B1 (no
Inventor
Thomas Reissmann
Horst Bauer
Peter Romeis
Berthold Roessler
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10245525A external-priority patent/DE10245525A1/de
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of NO20052041L publication Critical patent/NO20052041L/no
Publication of NO338309B1 publication Critical patent/NO338309B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Oppfinnelsen er relatert til farmasøytiske administrasjonsformer med opprettholdt frigjøring omfattende minst ett farmakologisk aktivt peptid. Oppfinnelsen angår også en fremgangsmåte for fremstilling, et kit som omfatter et lyofilisert peptid og en vandig løsning av et uorganisk salt eller eddiksyresalt og anvendelse av en vandig løsning av et uorganisk eller eddiksyresalt for fremstilling av en farmasøytisk administrasjonsform som frigir peptider på en kontinuerlig måte over et lengre tidsrom.
NO20052041A 2002-09-27 2005-04-26 Farmasøytisk gel-preparat, fremgangsmåte for fremstilling og kitt, samt anvendelsen av det farmasøytiske gel-preparatet for fremstilling av et medikament NO338309B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41422502P 2002-09-27 2002-09-27
DE10245525A DE10245525A1 (de) 2002-09-27 2002-09-27 Darreichungsform für pharmazeutisch aktive Peptide mit anhaltender Wirkstofffreigabe (sustained release) und Verfahren zu deren Herstellung
DE10320051 2003-04-26
PCT/EP2003/010732 WO2004030650A2 (de) 2002-09-27 2003-09-26 Darreichungsform für pharmazeutisch aktive peptide mit anhaltender wirkstofffreigabe (sustained release) und verfahren zu deren herstellung

Publications (2)

Publication Number Publication Date
NO20052041L true NO20052041L (no) 2005-06-10
NO338309B1 NO338309B1 (no) 2016-08-08

Family

ID=43646377

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052041A NO338309B1 (no) 2002-09-27 2005-04-26 Farmasøytisk gel-preparat, fremgangsmåte for fremstilling og kitt, samt anvendelsen av det farmasøytiske gel-preparatet for fremstilling av et medikament

Country Status (22)

Country Link
US (1) US7884071B2 (no)
EP (1) EP1565160B1 (no)
JP (1) JP4898118B2 (no)
KR (1) KR100633280B1 (no)
CN (1) CN100509053C (no)
AU (1) AU2003287950B2 (no)
BR (1) BRPI0314546B8 (no)
CA (1) CA2507524C (no)
DK (1) DK1565160T3 (no)
ES (1) ES2457019T3 (no)
HR (1) HRP20050371B1 (no)
IL (1) IL167415A (no)
IS (1) IS7750A (no)
ME (1) ME00509B (no)
MX (1) MXPA05003318A (no)
NO (1) NO338309B1 (no)
NZ (1) NZ538928A (no)
PL (1) PL208073B1 (no)
RS (2) RS52966B (no)
RU (1) RU2333743C2 (no)
WO (1) WO2004030650A2 (no)
ZA (1) ZA200502150B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2470665C2 (ru) * 2006-01-05 2012-12-27 Новартис Аг Способы профилактики и лечения ракового метастаза и разрежения кости, связанного с раковым метастазом
US20070219811A1 (en) * 2006-03-16 2007-09-20 Kim John S Method for using an internet-based CRM application to create an on-line leads marketplace
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
ES2447516T3 (es) * 2006-12-21 2014-03-12 Stryker Corporation Formulaciones de liberación sostenida que comprenden cristales BMP-7
ES2633453T3 (es) 2008-01-24 2017-09-21 Esperance Pharmaceuticals Constructos de fusión de dominios líticos y métodos de preparación y utilización de los mismos
TWI539959B (zh) 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
US8324347B2 (en) * 2009-02-24 2012-12-04 Institute For Systems Biology Methods of using halogenated peptides as internal standards for liquid chromatography-mass spectrometry
US8722088B2 (en) * 2009-05-01 2014-05-13 Ferring International Center S.A. Pharmaceutical compositions and methods for the treatment of prostate cancer
TR201809874T4 (tr) 2010-01-13 2018-07-23 Ipsen Pharma Sas Somatostati̇n analoglarinin sürekli̇ salimi i̇çi̇n farmasöti̇k bi̇leşi̇mleri̇n hazirlanmasi süreci̇.
CN102204889B (zh) * 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
EP2854831B1 (en) * 2012-06-01 2024-07-10 Ferring B.V. Manufacture of degarelix
ITMI20121638A1 (it) * 2012-10-02 2014-04-03 Marco Sbracia Utilizzo di degarelix nel trattamento dell'endometriosi e di patologie ad essa correlate
KR20210090298A (ko) 2012-10-30 2021-07-19 에스퍼란스 파마슈티컬스, 인코포레이티드 항체/약물 컨쥬게이트 및 이의 사용 방법
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
AU2018217064A1 (en) * 2017-01-31 2019-08-08 Veru Inc. Compositions and methods for long term release of Gonadotropin-releasing hormone (GnRH) antagonists
RU2020104475A (ru) * 2017-09-27 2021-08-02 Новел Фарма Инк. КОНЪЮГИРОВАННОЕ С ПАЛЬМИТИНОВОЙ КИСЛОТОЙ ПРОИЗВОДНОЕ GnRH ПРОЛОНГИРОВАННОГО ДЕЙСТВИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЕГО
WO2019148692A1 (zh) * 2018-01-31 2019-08-08 浙江三花制冷集团有限公司 一种电动阀及电动阀的制造方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
GB9108634D0 (en) * 1991-04-23 1991-06-12 Ciba Geigy Pharmaceutical compositions
DE4305225A1 (de) 1993-02-19 1994-08-25 Asta Medica Ag Neues Herstellverfahren für Cetrorelix Lyophilisat
US6828415B2 (en) 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
DE4342091A1 (de) * 1993-12-09 1995-06-14 Asta Medica Ag Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5942493A (en) * 1995-11-28 1999-08-24 Asta Medica Aktiengesellschaft LH-RH antagonists having improved action
US5916582A (en) * 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
DE69737635T2 (de) * 1996-08-30 2008-01-03 Peptech Ltd., North Ryde Formulierung zur verzögerten Freisetzung von Peptidagonisten und -analoga des GnRH
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
FR2776520B1 (fr) 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
WO2000004897A1 (en) * 1998-07-20 2000-02-03 Peptech Limited Bioimplant formulation
CO5160256A1 (es) * 1999-02-08 2002-05-30 Zentaris Ag Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
US7005418B1 (en) * 1999-09-23 2006-02-28 Zentaris Gmbh Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
US6635739B2 (en) 1999-10-15 2003-10-21 Theresa Siler-Khodr Non-mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy
DE10024451A1 (de) 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
GB0117057D0 (en) 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
IS7750A (is) 2005-03-17
CA2507524C (en) 2012-12-11
ES2457019T3 (es) 2014-04-24
HK1081855A1 (zh) 2006-05-26
KR20050084829A (ko) 2005-08-29
IL167415A (en) 2014-05-28
EP1565160A2 (de) 2005-08-24
HRP20050371B1 (hr) 2014-09-26
BRPI0314546B8 (pt) 2021-05-25
NO338309B1 (no) 2016-08-08
AU2003287950B2 (en) 2009-01-29
US20050282731A1 (en) 2005-12-22
AU2003287950A1 (en) 2004-04-23
JP4898118B2 (ja) 2012-03-14
BRPI0314546A8 (pt) 2015-12-15
KR100633280B1 (ko) 2006-10-16
MXPA05003318A (es) 2005-09-12
RU2005113163A (ru) 2005-10-10
RS20050247A (sr) 2007-06-04
NZ538928A (en) 2006-10-27
RS52966B (sr) 2014-02-28
HRP20050371A2 (en) 2005-06-30
CN100509053C (zh) 2009-07-08
JP2006505538A (ja) 2006-02-16
EP1565160B1 (de) 2014-01-22
PL208073B1 (pl) 2011-03-31
ZA200502150B (en) 2005-11-30
BR0314546A (pt) 2005-08-09
WO2004030650A2 (de) 2004-04-15
BRPI0314546B1 (pt) 2020-04-07
WO2004030650A3 (de) 2004-07-15
RU2333743C2 (ru) 2008-09-20
CA2507524A1 (en) 2004-04-15
US7884071B2 (en) 2011-02-08
CN1684703A (zh) 2005-10-19
DK1565160T3 (da) 2014-04-28
PL376446A1 (en) 2005-12-27
ME00509B (me) 2011-10-10

Similar Documents

Publication Publication Date Title
NO20052041L (no) Administrasjonsform for farmasoytisk aktive peptider med vedvarende frigivelse og fremgangsmate for fremstilling av denne
WO2008021088A3 (en) Salicylanilides enhance oral delivery of therapeutic peptides
US20040028613A1 (en) Dopamine agonist formulations for enhanced central nervous system delivery
NO20081889L (no) Fast vaksine formulering
US11052132B2 (en) Methods and compositions for treating cystic fibrosis
WO2002051390A3 (en) Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
ID29181A (id) Kombinasi formoterol dan garam tiotropium
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
WO2005055945A3 (en) Mucoadhesive drug delivery devices and methods of making and using thereof
TW200711657A (en) Pharmaceutical composition comprising botulinum toxin and recombinant human serum albumin
DK1290011T3 (da) Melphalan-derivater og deres anvendelse som cancer-kemoterapeutiske lægemidler
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
GB2367005A (en) Pharmaceutical formulations and methods comprising intranasal morphine
DK1349944T3 (da) Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens
WO2015183995A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
RU2010111139A (ru) Комбинированная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства
WO2006007354A3 (en) A drug/polymer complex, preferably ciprofloxacin/hpmc, its method of manufacturing using lyophilization and its use in an osmotic device
WO2007061829A3 (en) Pharmaceutical composition
DK1515745T3 (da) Anvendelse af forbindelser med biologiskaktivitet af vasoaktivt intestinalt peptid til behandlingen af sarkoidose
EP1571155A4 (en) PEPTIDES AND MEDICAL COMPOSITIONS WITH THE SAME
WO2012104462A1 (es) Heptapéptidos y su uso para el control de la hipertensión
NO20013851L (no) Salter med opprettholdt frigivning av farmasoytisk ative peptider samt fremstilling derav
ATE413187T1 (de) Pharmazeutische zusammensetzungen mit interferon- tau
AU2003246414A1 (en) Preparations for the intranasal application of selected cgrp antagonists derived from amino acids and a method for their production
WO2002050100A3 (en) Diaminodicarboxylic acid: peptide-based gemini surfactant compounds used for drug delivery

Legal Events

Date Code Title Description
MK1K Patent expired